Vera Therapeutics (VERA) CCO receives 20,000 RSUs and 40,000-share stock option grant

Rhea-AI Filing Summary

Vera Therapeutics Chief Commercial Officer Laurence Matthew Skelton reported new equity awards. On February 4, 2026, he received 20,000 shares of Class A Common Stock for $0, representing restricted stock units granted under Vera’s 2021 Equity Incentive Plan. After this award, he directly owned 65,800 Class A shares.

He was also granted a stock option for 40,000 shares of Class A Common Stock at an exercise price of $42.74 per share. One forty-eighth of the option vests on March 4, 2026, with the remainder vesting in equal monthly installments, while the RSUs vest in four equal annual installments each February 20 from 2027 through 2030, all subject to continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Skelton Laurence Matthew

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	40,000	$0.00	--
Grant/Award	Class A Common Stock	20,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 40,000 shares (Direct); Class A Common Stock — 65,800 shares (Direct)

Footnotes (1)

1. Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date. 1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Skelton Laurence Matthew

(Last) (First) (Middle)

C/O VERA THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 1200

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/04/2026		A		20,000(1)	A	$0	65,800	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$42.74	02/04/2026		A		40,000		(2)	02/03/2036	Class A Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date.

2. 1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.

	/s/ Joseph R. Young, Attorney-in-Fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Vera Therapeutics (VERA) report for February 4, 2026?

Vera Therapeutics reported equity awards to its Chief Commercial Officer on February 4, 2026. He received 20,000 Class A Common shares for $0 and a stock option for 40,000 shares at a $42.74 exercise price, both as part of compensation.

How many Vera Therapeutics (VERA) shares does the CCO own after this Form 4?

After the reported transaction, the Chief Commercial Officer beneficially owned 65,800 shares of Vera Therapeutics Class A Common Stock. This reflects the addition of 20,000 shares issued as restricted stock units granted under Vera’s 2021 Equity Incentive Plan.

What are the vesting terms of the 20,000 RSUs reported by Vera Therapeutics (VERA)?

The 20,000 RSUs vest in four equal installments on February 20 of 2027, 2028, 2029, and 2030. Each installment is rounded to the nearest whole share and requires the executive’s continuous service through the applicable vesting date.

What are the details of the 40,000-share stock option granted by Vera Therapeutics (VERA)?

The stock option covers 40,000 shares of Class A Common Stock at a $42.74 exercise price. One forty-eighth vests on March 4, 2026, with one forty-eighth vesting monthly thereafter on the same day, contingent on continued service through each vesting date.

Is the Vera Therapeutics (VERA) Chief Commercial Officer’s new equity grant direct or indirect ownership?

Both the RSUs and the stock option reported are held as direct ownership by the Chief Commercial Officer. The filing shows ownership form as “D” for direct, with no indication of indirect entities such as trusts or partnerships.

Under which plan were the RSUs in this Vera Therapeutics (VERA) Form 4 granted?

The 20,000 RSUs were granted under Vera Therapeutics’ 2021 Equity Incentive Plan. These RSUs represent shares of Class A Common Stock that will be delivered over time as they vest, assuming the executive continues providing service to the company.